Evidence map›Paper›PMID 39522959›Full record

ArticleInfluenza and other respiratory viruses2024

Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection-Increasing Community Access to Testing Program, United States, January-September 2023.

Allison Avrich Ciesla, Josephine Mak, Lauren E Roper, Katherine E Fleming-Dutra, Zachary R Smith, Ryan E Wiegand, Amadea Britton, Joseph Miller, Ruth Link-Gelles

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Influenza and other respiratory viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Allison Avrich CieslaNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0001-8739-1005
Josephine MakNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Lauren E RoperNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Katherine E Fleming-DutraNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Zachary R SmithOffice of Readiness and Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Ryan E WiegandNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Amadea BrittonNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Joseph MillerOffice of Readiness and Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Ruth Link-GellesNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Funding

CDC HHSUS Department of Health and Human Services
6 · The paper itself

Abstract

backgroundOn September 2, 2022, bivalent COVID-19 mRNA vaccines, were recommended to address reduced effectiveness of COVID-19 monovalent vaccines during SARS-CoV-2 Omicron variant predominance.

methodsUsing national pharmacy-based SARS-CoV-2 testing program data from January 15 to September 11, 2023, this test-negative, case-control design study assessed bivalent COVID-19 vaccine effectiveness (VE) against symptomatic infection.

resultsVE against symptomatic infection of a bivalent dose between 2 weeks and 1 month after bivalent vaccination ranged from 46% (95% CI: 38%-52%) for those aged ≥ 65 years to 61% (95% CI 41%-75%) for those aged 12-17 years.

conclusionBivalent vaccines protected against symptomatic infection. However, effectiveness waned over time, emphasizing the need to stay up to date with COVID-19 vaccination.

Indexed as

COVID-19COVID-19 VaccinesmRNA VaccinesSARS-CoV-2Vaccine EfficacyAdolescentAdultAgedCase-Control StudiesChildFemaleHumansMaleMiddle AgedUnited StatesVaccinationCOVID-19 VaccinesmRNA VaccinesVaccines, SyntheticBivalentCOVID‐19SARS‐CoV‐2Symptomatic Infection

Identifiers

PMID39522959
PMCPMC11550894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.